BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bitzan M, Zieg J. Influenza-associated thrombotic microangiopathies. Pediatr Nephrol 2018;33:2009-25. [PMID: 28884355 DOI: 10.1007/s00467-017-3783-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Alislambouli M, Veras Victoria A, Matta J, Yin F. Acquired thrombotic thrombocytopenic purpura following Pfizer COVID-19 vaccination. EJHaem 2021. [PMID: 34909764 DOI: 10.1002/jha2.342] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
2 Haller H. Thrombotische Mikroangiopathie und Niere. Nephrologe 2019;14:100-7. [DOI: 10.1007/s11560-019-0320-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
3 Ishiguro T, Kojima A, Shimizu T, Mita N, Kuroiwa S, Takayanagi N. Combined hemophagocytic syndrome and thrombotic microangiopathy due to mixed infection with influenza virus and pneumococcal pneumonia. Clin Case Rep 2019;7:131-4. [PMID: 30656026 DOI: 10.1002/ccr3.1842] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 Edoka I, Kohli-Lynch C, Fraser H, Hofman K, Tempia S, McMorrow M, Ramkrishna W, Lambach P, Hutubessy R, Cohen C. A cost-effectiveness analysis of South Africa's seasonal influenza vaccination programme. Vaccine 2021;39:412-22. [PMID: 33272702 DOI: 10.1016/j.vaccine.2020.11.028] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Anderson A, Seddon M, Shahzad K, Lunevicius R. Post-COVID-19 vaccination occurrence of splenic infarction due to arterial thrombosis. BMJ Case Rep 2021;14:e243846. [PMID: 34876440 DOI: 10.1136/bcr-2021-243846] [Reference Citation Analysis]
6 Hara A, Hara K, Komeda T, Ogura E, Miyazawa S, Kobayashi C, Fujiwara M, Yoshida M, Urushihara H. Comparison of the incidence of bleeding between baloxavir marboxil and other anti-influenza drugs among outpatients with influenza virus infection: A retrospective cohort study using an employment-based health insurance claims database in Japan. Pharmacoepidemiol Drug Saf 2021. [PMID: 34881477 DOI: 10.1002/pds.5392] [Reference Citation Analysis]
7 Rassner M, Baur R, Wäsch R, Schiffer M, Schneider J, Mackensen A, Engelhardt M. Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma. BMC Nephrol 2021;22:32. [PMID: 33461512 DOI: 10.1186/s12882-020-02226-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Coelho Júnior JL, Israel KCP, Machado CEE, Muniz MPR, Gatto GC, Barros FHS, Cunha KA, de Lacerda MVG, Neves PDMM, Silva GEB. Thrombotic microangiopathy associated with arboviral infection: Report of 3 cases. PLoS Negl Trop Dis 2021;15:e0009790. [PMID: 34648498 DOI: 10.1371/journal.pntd.0009790] [Reference Citation Analysis]
9 El Sissy C, Saldman A, Zanetta G, Martins PV, Poulain C, Cauchois R, Kaplanski G, Venetz JP, Bobot M, Dobosziewicz H, Daniel L, Koubi M, Sadallah S, Rotman S, Mousson C, Pascual M, Frémeaux-Bacchi V, Fakhouri F. COVID-19 as a potential trigger of complement-mediated atypical HUS. Blood 2021;138:1777-82. [PMID: 34482396 DOI: 10.1182/blood.2021012752] [Reference Citation Analysis]
10 De Fabritiis M, Angelini ML, Fabbrizio B, Cenacchi G, Americo C, Cristino S, Lifrieri MF, Cappuccilli M, Spazzoli A, Zambianchi L, Mosconi G. Renal Thrombotic Microangiopathy in Concurrent COVID-19 Vaccination and Infection. Pathogens 2021;10:1045. [PMID: 34451509 DOI: 10.3390/pathogens10081045] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Sheerin NS, Glover E. Haemolytic uremic syndrome: diagnosis and management. F1000Res 2019;8:F1000 Faculty Rev-1690. [PMID: 31598213 DOI: 10.12688/f1000research.19957.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
12 Rubinstein JD, Zhu X, Lutzko C, Leemhuis T, Cancelas JA, Jodele S, Bollard CM, Hanley PJ, Davies SM, Grimley MS, Nelson AS. Complement inhibition does not impair the clinical antiviral capabilities of virus-specific T-cell therapy. Blood Adv 2020;4:3252-7. [PMID: 32697816 DOI: 10.1182/bloodadvances.2020002252] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Piedrafita A, Ribes D, Cointault O, Chauveau D, Faguer S, Huart A. Plasma exchange and thrombotic microangiopathies: From pathophysiology to clinical practice. Transfus Apher Sci 2020;59:102990. [PMID: 33272850 DOI: 10.1016/j.transci.2020.102990] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Onkarappa Mangala Y, Sweeney JD. Influenza-associated thrombotic thrombocytopenic purpura: A report of two cases and a brief review of the literature. Vox Sang 2021. [PMID: 34841536 DOI: 10.1111/vox.13227] [Reference Citation Analysis]
15 Syed S, Hakala P, Singh AK, Lapatto HAK, King SJ, Meri S, Jokiranta TS, Haapasalo K. Role of Pneumococcal NanA Neuraminidase Activity in Peripheral Blood. Front Cell Infect Microbiol 2019;9:218. [PMID: 31297339 DOI: 10.3389/fcimb.2019.00218] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
16 Jodele S, Köhl J. Tackling COVID-19 infection through complement-targeted immunotherapy. Br J Pharmacol 2021;178:2832-48. [PMID: 32643798 DOI: 10.1111/bph.15187] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
17 Haseeb AA, Solyman O, Abushanab MM, Abo Obaia AS, Elhusseiny AM. Ocular Complications Following Vaccination for COVID-19: A One-Year Retrospective. Vaccines (Basel) 2022;10:342. [PMID: 35214800 DOI: 10.3390/vaccines10020342] [Reference Citation Analysis]
18 Silecchia V, D'Onofrio G, Valerio E, Rubin G, Vidal E, Murer L. Influenza-associated hemolytic uremic syndrome: The pathogenic role of the virus. Clin Nephrol Case Stud 2021;9:45-8. [PMID: 33884256 DOI: 10.5414/CNCS110219] [Reference Citation Analysis]
19 Sissa C, Al-Khaffaf A, Frattini F, Gaiardoni R, Mimiola E, Montorsi P, Melara B, Amato M, Peyvandi F, Franchini M. Relapse of thrombotic thrombocytopenic purpura after COVID-19 vaccine. Transfus Apher Sci 2021;60:103145. [PMID: 33888416 DOI: 10.1016/j.transci.2021.103145] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
20 Lim J, Kim M, Kim Y, Han M, Jung H, Choi J, Cho J, Kim C, Kim Y, Park S. New-Onset Kidney Diseases after COVID-19 Vaccination: A Case Series. Vaccines 2022;10:302. [DOI: 10.3390/vaccines10020302] [Reference Citation Analysis]
21 Martin SM, Balestracci A, Puyol I, Toledo I, Cao G, Arizeta G. Uncommon Presentation of Atypical Hemolytic Uremic Syndrome: A Case Report. Indian J Nephrol 2021;31:478-81. [PMID: 34880559 DOI: 10.4103/ijn.IJN_271_20] [Reference Citation Analysis]
22 Palma LMP, Sridharan M, Sethi S. Complement in Secondary Thrombotic Microangiopathy. Kidney Int Rep 2021;6:11-23. [PMID: 33102952 DOI: 10.1016/j.ekir.2020.10.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
23 Colares VS, Miranda SM, Andrade LGM, Palma LMP, Castro MCR, Silva CAB, Penido MGMG, Sobral R, Vaisbich MH. COMDORA-SBN recommendations for patients with rare kidney diseases in relation to the Covid-19 pandemic. J Bras Nefrol 2020;42:36-40. [PMID: 32877497 DOI: 10.1590/2175-8239-JBN-2020-S109] [Reference Citation Analysis]
24 Alhomoud M, Alhobayb T, Armitage K. COVID-19 infection triggering Thrombotic Thrombocytopenic Purpura. IDCases 2021;26:e01256. [PMID: 34458098 DOI: 10.1016/j.idcr.2021.e01256] [Reference Citation Analysis]
25 Dalkıran T, Kandur Y, Kara EM, Dağoğlu B, Taner S, Öncü D. Thrombotic Microangiopathy in a Severe Pediatric Case of COVID-19. Clin Med Insights Pediatr 2021;15:11795565211049897. [PMID: 34707424 DOI: 10.1177/11795565211049897] [Reference Citation Analysis]